Article

Strategies For API Solubility And Bioavailability Enhancement: Selecting Technologies And Excipients

Source: Thermo Fisher Scientific

By Sanjay Konagurthu, Ph. D., Senior Director, Science and Innovation, and Tom Reynolds, Principal Scientist

Strategies For API Solubility And Bioavailability Enhancement: Selecting Technologies And Excipients

Low aqueous solubility is a major problem encountered during the formulation development of drug molecules. A drug that is not able to dissolve in a patient’s gastrointestinal tract is unable to be systemically absorbed and, as a result, carries a higher risk of failure during development.1 Therefore, with about 70 to 90 percent of the drugs in development falling in the two low-solubility classes of the Biopharmaceutical Classification System (BCS),2 it is critical that formulation scientists use the most appropriate solubility enhancement technology and formulation strategies to improve the bioavailability of poorly soluble drugs.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: